Developing a coordinated survivorship care plan between oncologists and primary care physicians is a top priority for cancer patients. To better understand what goes into this, Dr. Jennifer Caudle is joined by Dr. Maryam Lustberg, Director of The Breast Cancer Center at the Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, to discuss the role of the primary care physician in survivorship care for breast cancer patients.

Has our understanding of HER2 status changed? Dr. Pavanai Chalsani from the University of Arizona Cancer Center dives into the reclassification of HER2 status and shares emerging clinical trial data.

Getting a better understanding of your patient’s challenges might help you improve their care and streamline the path from diagnosis to treatment. To better understand this, Dr. Jacob Sands sits down with Dr. Millie Das from the Stanford School of Medicine to share strategies to choose the best course of care.

As DNA damage response therapies move beyond PARP inhibitors, what do we need to know? Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares insights and takeaways from his presentation at the 2021 San Antonio Breast Cancer Symposium.

With a lack of clear standards of care in the post CDK4/6 inhibitor setting, a new study aims to address this unmet need. Dr. Timothy Yap from the University of Texas MD Anderson Cancer Center shares clinical trial data and its impact on cancer patients.

What do we need to know about the management of the axilla for patients with early-stage breast cancer? Dr. Terry Mamounas shares highlights from his presentation at the 2021 San Antonio Breast Cancer Symposium titled, “Refining Axillary Management After Neoadjuvant Chemotherapy - What Does the Evidence Support?”

What do we need to know about the ablation of oligometastatic disease? Dr. Steven J. Chmura shares his vantage point on this topic and others from the 2021 San Antonio Breast Cancer Symposium.

The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.

RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.

With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.